A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

Publication date: Sep 17, 2025

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Concepts Keywords
Disease Long COVID
Investigator Post-COVID condition
Pcr Post-COVID fatigue
Recent Post-COVID syndrome
Vaccination REGENECYTE
Umbilical cord blood

Semantics

Type Source Name
disease MESH Post-COVID Condition
disease MESH Neurological disorders
disease MESH COVID-19
disease MESH immune
disease MESH chronic
disease MESH complications
disease MESH syndrome

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *